New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
16:31 EDTRIMM, DELL, JNJ, IIVI, BOX, VZ, TRV, ARNA, MSFT, DDOn The Fly: Closing Wrap
Stocks on Wall Street were slightly higher after four Dow components reported mixed quarterly results before the bell. The earnings calendar is fairly heavy again after the bell, as investors receive results from tech giants Google (GOOG) and International Business Machines (IBM) among those reporting... ECONOMIC EVENTS: In the U.S., sales of existing homes unexpectedly dropped 1% in December to a 4.94M annual rate, versus expectations for sales to increase to a 5.1M rate. Two regional Fed surveys were also reported, with the Chicago Fed National Activity Index slipping but remaining positive at 0.02, while the Richmond Fed Manufacturing Survey plunged 17 points to -12... COMPANY NEWS: Among the four Dow members reporting results, Travelers (TRV) was the leader, gaining $1.64, or 2.15%, to $77.95 after its better than expected earnings. Shares of DuPont (DD) and Verizon (VZ) were also higher. Johnson & Johnson (JNJ) slid 54c, or 0.74%, to $72.69 after its quarterly report in spite of announcing plans to explore options for its Ortho Clinical Diagnostics unit, including a potential sale or spin-off... Microsoft (MSFT) is in talks to invest between $1B-$3B as part of a leveraged buyout of Dell (DELL), according to CNBC's David Faber. Dell spiked higher following the news, finishing up 28c, or 2.18%, at $13.12, while Microsoft lost 8c, or 0.29%, to $27.17... MAJOR MOVERS: Among the notable gainers was SeaCube (BOX), up $2.84, or 13.99%, to $23.14 after agreeing to be acquired by Ontario Teachers' Pension for $23 per share. Also higher were shares of Research In Motion (RIMM), which rose $2.06, or 13.01%, to $17.90 after its CEO reportedly said it may license the BB10 operating system and shares were upgraded to Outperform at Scotia Capital with a $23 price target. Among the noteworthy losers was Arena Pharmaceuticals (ARNA), which lost 95c, or 9.72%, to $8.82 after the European Medicines Agency asked it to address issues with its anti-obesity drug. Also lower were shares of II-VI (IIVI), down $1.87, or 9.51%, to $17.80 after the company's Q2 report fell short of expectations and its FY13 guidance came in below Street estimates... INDICES: The Dow was up 62.43, or 0.46%, to 13,712.13; the Nasdaq was up 8.47, or 0.27%, to 3,143.18; and the S&P 500 was up 6.53, or 0.44%, to 1,492.51.
News For TRV;JNJ;DD;VZ;DELL;MSFT;BOX;RIMM;ARNA;IIVI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 9, 2014
09:38 EDTVZActive equity options trading
Subscribe for More Information
07:40 EDTVZVerizon competition increased, company should be able to respond, says Canaccord
Subscribe for More Information
07:32 EDTVZUBS to hold a conference
Subscribe for More Information
06:54 EDTTRVTravelers initiated with a Neutral at JPMorgan
Subscribe for More Information
06:27 EDTMSFTSamsung, white-box makers to benefit from Microsoft Mobile exit, DigiTimes says
Subscribe for More Information
06:15 EDTVZVerizon downgraded at RW Baird
As previously reported, Baird downgraded Verizon to Neutral from Outperform. The firm downgraded shares citing last night's negative pre-announcement due to increasing competitive concerns, margin pressures, higher churn, and full valuation. Price target lowered to $50 from $54.
06:01 EDTVZVerizon downgraded to Neutral from Outperform at RW Baird
Subscribe for More Information
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
18:24 EDTVZOn The Fly: After Hours Movers
Subscribe for More Information
17:05 EDTVZVerizon sees Q4 impacts of promotional offers will pressure wireless EBITDA, EPS
Subscribe for More Information
13:21 EDTMSFTMicrosoft files appeal in case on customer data in Ireland
Microsoft said on its blog that it has filed an appeal in its ongoing case challenging a U.S. government search warrant for customer data stored in Ireland. Microsoft said it filed the appeal after a U.S. district court judge rejected the company’s argument that the warrant is illegal because it calls for the seizure of emails stored outside the United States. Reference Link
12:40 EDTMSFTOn The Fly: Midday Wrap
Subscribe for More Information
10:44 EDTMSFTDigital River grants Microsoft extestion to decide on renewing pact
Subscribe for More Information
10:04 EDTMSFTAccenture and Microsoft launch hybrid cloud platform
Subscribe for More Information
06:47 EDTARNAArena says Teva files marketing authorization of Belviq in Israel
Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.
06:45 EDTARNAArena says Eisai withdraws Belviq application in Canada
Subscribe for More Information
06:44 EDTARNAArena Pharmaceuticals says 'small number' of Belviq labels incomplete
Subscribe for More Information
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use